Peer-reviewed veterinary case report
Akt signaling activity linked to prognosis in dog soft tissue sarcoma
By Miyanishi, Kyohei et al.·Published in Journal of comparative pathology·2023·Joint Faculty of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Activation of the Akt signalling pathway as a prognostic indicator in canine soft tissue sarcoma.
- Species:
- dog
Plain-English summary
A study looked at dogs with soft tissue sarcoma, a type of tumor that can develop in various tissues. Researchers found that a specific protein marker called phospho-Akt was linked to how aggressive the tumor was and could help predict the dog's prognosis. Higher levels of phospho-Akt were found in cases where the cancer had returned or spread. This means that testing for phospho-Akt, along with other markers, might help vets determine the best treatment options and understand the likely outcome for dogs with this type of cancer.
People also search for: dog soft tissue sarcoma prognosis · phospho-Akt in dogs · treatment for dog cancer · dog tumor markers · recurrent dog cancer treatment
Abstract
Canine soft tissue sarcoma (STS) is relatively common in dogs and is the generic term for tumours that originate from mesenchymal cells. While histopathological grade and immunolabelling with Ki-67 have been used for estimating prognosis, additional indicators are needed for predicting prognosis. Aberrant cell signalling pathways may contribute to disease activity and, therefore, prognostic markers. However, their role in canine STS remains poorly understood. The aim of this study was to investigate expression of phosphorylated Akt (phospho-Akt) and phosphorylated S6 (phospho-S6) as potential prognostic indicators. Immunohistochemical labelling was conducted on clinical samples of canine STS (n = 67). We found that phospho-Akt expression was positively correlated with histopathological grade (P = 0.001) and Ki-67 index (P <0.01). There was no apparent relationship between the type of STS and the expression of phospho-Akt. The number of cases that expressed phospho-S6, which is the downstream molecule of the Akt signalling pathway, was higher in immunopositive phospho-Akt cases than in immunonegative phospho-Akt cases (P <0.0001). Furthermore, phospho-Akt expression was significantly higher in recurrent and metastatic cases. We also confirmed that phosphorylation of Akt occurred in conjunction with S6 phosphorylation in three canine STS cell lines. These results suggest that immunolabelling for phospho-Akt, phospho-S6 and Ki-67 could potentially be used as a prognostic indicator and therapeutic target in canine STS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37839309/